A Phase 2b-ready Cyclerion Therapeutics drug candidate for a rare mitochondrial disease gets new life under a new startup led by a familiar face. Tisento Therapeutics acquired the Cyclerion drug and is backed by a Series A round financing.
In 2021 biotech had a median deal of $10 million and an average deal of $36.9 million, according to the report by PitchBook Data. Comparatively, medtech locked in an median of $3.9 million and $12.6 million average.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Eli Lilly is entering the field of protein-degrading drugs through a partnership with Lycia Therapeutics, a startup whose technology goes further than the first wave of such drugs. Lilly paid $35 million to begin the alliance, which spans up to five drugs.
I have a confession to make . . . I’m only an intern at MedCity News. I just graduated high school and even though I’m young, I’ve already gotten a jump on my future as a journalist. Like many high school graduates, I want to change the world someday. There’s a secret to changing the […]
Everyone likes to talk about funding for digital health – Y Combinator is doing biotech now! Andreesen Horowitz gets into health tech! Deals and dollars look great in Q1 2014! It’s not as easy to make cheery slide decks about funding for the rest of the healthcare startup world: pharma, medical devices and bio tech […]